Business Wire

CA-SYNACK

13.6.2019 15:02:06 CEST | Business Wire | Press release

Share
Finally, Smart Cybersecurity: The Optimal Combination of Ethical Hackers and Artificial Intelligence

The debate on how we should best use Artificial Intelligence is ongoing, but no one can argue against its benefits when used to augment human work. Take self-driving cars: when Artificial Intelligence is used alongside humans, it provides features like improved safety and predictive driving. The same is true in cybersecurity; we will always need the creativity of human intelligence to beat the human adversary. However, we can also augment those humans with smart technology to help make them more effective, cover a wider attack surface, and speed up their time to find and fix vulnerabilities. Synack, the trusted leader in crowdsourced security, has just launched the industry’s first cybersecurity platform to integrate crowdsourced human intelligence augmented with artificial intelligence to help security teams work smarter, not harder, to protect digital assets continuously and at scale.

The impact? Intelligence that helps security teams find and fix vulnerabilities faster and build more secure code.

The stakes are high - cybercrime is predicted to cost the world $6 trillion annually by 2021- and human capital to protect the cybersphere is lacking; 3.5 million cybersecurity jobs are predicted to go unfilled by 2021 (Cybersecurity Ventures).

“While humans can’t scale, machines can’t think. More than 80% of the vulnerabilities that our Synack Red Team find in our clients’ assets aren’t detected by a scanner. We will always need the creativity of human intelligence. But to scale at the pace of the threats, we need to automate wherever possible and keep building technology to test ‘smarter’,” Dr. Mark Kuhr, Synack CTO and co-founder said.

Synack’s industry-leading cybersecurity Platform 2.0 delivers a smarter, more efficient security test through the use of smart platform technology and new product, SmartScan. Together, the platform’s new features and advanced technology seamlessly orchestrate the optimal combination of human and machine intelligence for more effective, efficient security on a 24/7/365 basis. SmartScan helps security teams increase their attack surface coverage and gain new insight by continuously scanning for suspected vulnerabilities and engaging the company’s crowdsourced network of ethical hackers to validate them. The augmented intelligence offered by Synack’s “smart” Crowdsourced Security Platform, if applied to all penetration testing, would add 4x more efficiency to security teams.

Additional benefits of Synack’s Crowdsourced Security Platform to security teams include:

  • Noise Reduction: 99.98% of total noise is reduced by leveraging Synack SmartScan in combination with Synack Red Team crowdsourced vulnerability triage and patch verification services.
  • Higher Value: The latest version of Synack’s platform with augmented intelligence increases the ROI of Synack’s original offering by over 50%. Customers will see a 159% ROI with the Synack Crowdsourced Security Platform in comparison to a traditional penetration test. And if comparing the Synack platform to a traditional scanner, they will get a 262% ROI. If deployed universally across application security testing, SmartScan would add ~$3B in security value back to the market.

In addition to SmartScan, Synack’s Crowdsourced Security Platform 2.0 includes other new and enhanced features; Apollo, a machine learning and automation engine that optimizes the integration of humans and technology, superior analytics and reporting, and LaunchPoint+, a secure testing gateway with added researcher endpoint control and enhanced workspaces to support privacy for highly regulated environments. Synack Red Team researchers said they were “happy with the [LaunchPoint+] concept”, “a fan of the increased bandwidth”, and could “definitely see myself using this a lot” in response to Synack launching the only crowdsourced security testing with endpoint control baked into the platform.

About Synack

Synack, the most trusted crowdsourced security platform, delivers continuous and scalable penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create an efficient and effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .

Contact:

Ellie McCardwell, Synack Communications press@synack.com

Link:

ClickThru

Social Media:

https://www.facebook.com/synack/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye